IP Library › Granted Patent US 12,702,570
Granted Patent B2
US 12,702,570 · App. 17/733,768 · Granted Aug 11, 2026

Impaction cradle

Inventors: Tim Yoko (Granger, IN); Amanda Szalkowski (Winona Lake, IN); Jeffery A. VanDiepenbos (New Paris, IN)
Assignee: Zimmer, Inc.
A61F2/461A61F2/3859A61F2/389A61F2002/4681
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,702,570
App. No.
17/733,768
Filed
Apr 29, 2022
Granted
Aug 11, 2026
Kind
B2
Art Unit
3774
USPC
623/22.12
Abstract

An impaction cradle ( 50 ) for supporting a femoral ( 10 ) or tibial ( 70 ) implant on a planar support surface such as a tabletop. The impaction cradle can orient the femoral or tibial implant on the impaction cradle such that an attachment feature of the implant for an intramedullary stem or metaphyseal sleeve is aligned with a vertical plane or parallel to the true vertical axis. In this position, the intramedullary stem or metaphyseal sleeve can be impacted along a generally vertical axis to drive the intramedullary stem or metaphyseal sleeve along an impaction axis parallel to a true vertical axis or positioned within a vertical plane. The generally vertical impaction angle can be easier for medical practitioners to accurately impact the intramedullary stem or metaphyseal sleeve, which lowers the risk of damage to the intramedullary stem, metaphyseal sleeve, or the femoral or tibial implant.

Claims (35)

1 . An impaction cradle for supporting a tibial implant during impaction of an intramedullary stem into an attachment port of the tibial implant along an impaction axis, comprising:

a rectangular base defining a rectangular outer perimeter and having a planar body defining a base plane, the planar body further comprising a top surface, an angled surface recessed from the top surface and oriented transverse to the base plane, and a base surface opposite the angled surface, the angled surface including a first recessed planar segment and a second stepped recessed planar segment that lies closer to the top surface of the planar body than the first recessed planar segment;

wherein the top surface and the base surface are parallel to the base plane;

wherein the angled surface is transverse to the base plane at a transverse angle of about 3 degrees corresponding to a posterior slope of the tibial implant; and

wherein the angled surface is shaped to receive a lateral condyle portion and a medial condyle portion of the tibial implant.

2 . The impaction cradle of claim 1 , wherein the angled surface is recessed from a top surface of the planar body.

3 . The impaction cradle of claim 2 , wherein the top surface is substantially parallel to the base surface.

4 . The impaction cradle of claim 3 , wherein the planar body further comprises a second angled surface recessed from the base surface, the second angled surface configured to receive a cradle element for a femoral implant.

5 . The impaction cradle of claim 1 , wherein the angled surface is shaped to receive and be in contact with a medial articulating surface of the tibial implant and a lateral articulating surface of the tibial implant.

6 . A tibial implant system, comprising:

a tibial implant having an attachment port;

an intramedullary stem configured to be impacted into the attachment port along an impaction axis; and

an impaction cradle, comprising:

a rectangular base defining a rectangular perimeter and having a planar body including an upper planar surface defining a base plane and a lower planar surface opposite the upper planar surface and parallel thereto, the planar body further comprising an angled surface recessed from the upper planar surface and oriented transverse to the base plane to orient the tibial implant such that the impaction axis is generally vertical, the angled surface including a first recessed planar segment and a second stepped recessed planar segment that lies closer to the upper planar surface of the planar body than the first recessed planar segment, wherein the angled surface is shaped to receive a lateral tibial condyle portion and a medial tibial condyle portion of the tibial implant.

7 . The tibial implant system of claim 6 , wherein:

the medial tibial condyle portion comprises a medial articulating surface; and

the lateral tibial condyle portion comprises a lateral articulating surface;

wherein the medial articulating surface and the lateral articulating surface cooperate to define an articulating plane.

8 . The tibial implant system of claim 7 , wherein the angled surface is transverse to the base plane at a transverse angle corresponding to a posterior slope of the tibial implant.

9 . The tibial implant system of claim 8 , wherein the transverse angle is about 3 degrees.

10 . The tibial implant system of claim 7 , wherein the articulating plane is parallel to the angled surface when the tibial implant is received on the impaction cradle.

11 . The tibial implant system of claim 6 , wherein the tibial implant includes a detent located within the attachment port.

12 . The tibial implant system of claim 11 , wherein the intramedullary stem includes a notched portion configured to engage the detent to lock the intramedullary stem to the tibial implant.

13 . A knee implant system, comprising:

a tibial implant having a tibial attachment port;

a tibial intramedullary stem configured to be impacted into the tibial attachment port along a tibial impaction axis; and

an impaction cradle, comprising:

a rectangular base defining a rectangular outer perimeter and having a planar body including an upper planar surface defining a base plane, a lower planar surface opposite the upper planar surface and parallel thereto, a tibial angled surface recessed from the upper planar surface for receiving the tibial implant, and a femoral angled surface for receiving a cradle element;

wherein the tibial angled surface is oriented transverse to the base plane to orient the tibial implant such that the impaction axis is generally vertical;

wherein the tibial angled surface includes a first recessed planar segment and a second stepped recessed planar segment that lies closer to the upper planar surface of the planar body than the first recessed planar segment.

14 . The knee implant system of claim 13 , wherein the impaction cradle further comprises:

a cradle element having at least one femoral support surface for receiving a femoral implant, the femoral support surface defining a femoral support plane.

15 . The knee implant system of claim 14 , further comprising:

a femoral implant having a femoral attachment port; and

a femoral intramedullary stem configured to be impacted into the femoral attachment port along a femoral impaction axis.

Continuity (3)
Continuation 16652896 · Oct 10, 2018
Provisional Application 62570889 · Oct 11, 2017
Related Publication 20220249251A1 · Aug 11, 2022
References Cited (190)
US 4751922A · Dipietropolo · 1988 [cited by applicant]
US 5282861A · Kaplan · 1994 [cited by applicant]
US 5702461A · Pappas et al. · 1997 [cited by applicant]
US 6159216A · Burkinshaw et al. · 2000 [cited by applicant]
US 6171342B1 · O'Neil et al. · 2001 [cited by applicant]
US 6258093B1 · Edwards et al. · 2001 [cited by applicant]
US 6902583B2 · Gerbec et al. · 2005 [cited by applicant]
US 6911100B1 · Gibbs et al. · 2005 [cited by applicant]
US 7291174B2 · German et al. · 2007 [cited by applicant]
US 7799085B2 · Goodfried et al. · 2010 [cited by applicant]
US 8187280B2 · May et al. · 2012 [cited by applicant]
US 8535385B2 · Hanssen et al. · 2013 [cited by applicant]
US 8556900B2 · Yoko et al. · 2013 [cited by applicant]
US 8721733B2 · Bonitati · 2014 [cited by applicant]
US 8979847B2 · Belcher et al. · 2015 [cited by applicant]
US 8998996B2 · James et al. · 2015 [cited by applicant]
US 9603649B2 · Matyas et al. · 2017 [cited by applicant]
US 10182830B2 · Amanatullah · 2019 [cited by applicant]
US 10987225B2 · Yoko et al. · 2021 [cited by applicant]
US 11141290B2 · Yoko et al. · 2021 [cited by applicant]
US 11351041B2 · Yoko et al. · 2022 [cited by applicant]
US 20030050643A1 · Taft · 2003 [cited by applicant]
US 20030097133A1 · Green et al. · 2003 [cited by applicant]
US 20030158606A1 · Coon · 2003 [cited by examiner]
US 20040049286A1 · German et al. · 2004 [cited by applicant]
US 20050107886A1 · Crabtree · 2005 [cited by examiner]
US 20050124998A1 · Coon et al. · 2005 [cited by applicant]
US 20050177122A1 · Berba et al. · 2005 [cited by applicant]
US 20060241635A1 · Stumpo et al. · 2006 [cited by applicant]
US 20070101827A1 · Quan et al. · 2007 [cited by applicant]
US 20090149964A1 · May · 2009 [cited by examiner]
US 20090270927A1 · Perrow et al. · 2009 [cited by applicant]
US 20090306787A1 · Crabtree et al. · 2009 [cited by applicant]
US 20100063507A1 · Sidebotham et al. · 2010 [cited by applicant]
US 20110029090A1 · Zannis · 2011 [cited by examiner]
US 20110082559A1 · Hartdegen · 2011 [cited by examiner]
US 20120143204A1 · Blaylock et al. · 2012 [cited by applicant]
US 20120245700A1 · Sidebotham · 2012 [cited by applicant]
US 20120310246A1 · Belcher et al. · 2012 [cited by applicant]
US 20130006370A1 · Wogoman et al. · 2013 [cited by applicant]
US 20130172892A1 · Servidio et al. · 2013 [cited by applicant]
US 20130304221A1 · Blaylock et al. · 2013 [cited by applicant]
US 20130325019A1 · Thomas et al. · 2013 [cited by applicant]
US 20140228846A1 · Roby et al. · 2014 [cited by applicant]
US 20140276838A1 · Tsukayama et al. · 2014 [cited by applicant]
US 20140276859A1 · Chaney et al. · 2014 [cited by applicant]
US 20140277528A1 · Mines et al. · 2014 [cited by applicant]
US 20140277540A1 · Leszko et al. · 2014 [cited by applicant]
US 20140277546A1 · Major et al. · 2014 [cited by applicant]
US 20150127005A1 · Mcmanus · 2015 [cited by applicant]
US 20150190150A1 · Primiano et al. · 2015 [cited by applicant]
US 20150216667A1 · Monaghan · 2015 [cited by applicant]
US 20160081758A1 · Bonutti · 2016 [cited by applicant]
US 20160367381A1 · Chaney et al. · 2016 [cited by applicant]
US 20170000503A1 · Keefer et al. · 2017 [cited by applicant]
US 20170172748A1 · Angibaud et al. · 2017 [cited by applicant]
US 20170231642A1 · Chaney et al. · 2017 [cited by applicant]
US 20170281199A1 · Amanatullah · 2017 [cited by applicant]
US 20190038417A1 · Yoko et al. · 2019 [cited by applicant]
US 20190105159A1 · Dees et al. · 2019 [cited by applicant]
US 20190110906A1 · Yoko et al. · 2019 [cited by applicant]
US 20190110907A1 · Yoko et al. · 2019 [cited by applicant]
US 20200289290A1 · Yoko et al. · 2020 [cited by applicant]
US 20210353436A1 · Yoko et al. · 2021 [cited by applicant]
US 20220249251A1 · Yoko et al. · 2022 [cited by applicant]
US 20260069435A1 · Yoko et al. · 2026 [cited by applicant]
AU 2023202761 · 2025 [cited by applicant]
CN 101744675A · 2010 [cited by applicant]
CN 104013456A · 2014 [cited by applicant]
CN 104042303A · 2014 [cited by applicant]
CN 104042368A · 2014 [cited by applicant]
CN 104042369A · 2014 [cited by applicant]
CN 111212616A · 2020 [cited by applicant]
CN 114652492 · 2022 [cited by applicant]
EP 0440371 · 1991 [cited by applicant]
EP 4248886 · 2026 [cited by applicant]
JP H05103790 · 1993 [cited by applicant]
JP H08506260 · 1996 [cited by applicant]
JP 2008515498 · 2008 [cited by applicant]
JP 2014176658A · 2014 [cited by applicant]
JP 2020536670A · 2020 [cited by applicant]
JP 7125480 · 2022 [cited by applicant]
JP 2022140793 · 2022 [cited by applicant]
JP 7450676 · 2024 [cited by applicant]
JP 2024059963 · 2024 [cited by applicant]
JP 7699683B2 · 2025 [cited by applicant]
JP 2025120473A · 2025 [cited by applicant]
WO WO03045257A2 · 2003 [cited by applicant]
WO 2012021779 · 2012 [cited by applicant]
WO WO2013086340A1 · 2013 [cited by applicant]
WO WO2013102089A1 · 2013 [cited by applicant]
WO WO2014063084A1 · 2014 [cited by applicant]
WO WO2019075066A1 · 2019 [cited by applicant]
WO WO2019075078A1 · 2019 [cited by applicant]
“U.S. Appl. No. 16/047,463, Corrected Notice of Allowability mailed Mar. 31, 2021”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/047,463, Final Office Action mailed Sep. 4, 2020”, 15 pgs. [cited by applicant]
“U.S. Appl. No. 16/047,463, Non Final Office Action mailed Feb. 21, 2020”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 16/047,463, Notice of Allowance mailed Dec. 14, 2020”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/047,463, Response filed May 21, 2020 to Non Final Office Action mailed Feb. 21, 2020”, 18 pgs. [cited by applicant]
“U.S. Appl. No. 16/047,463, Response filed Oct. 28, 2020 to Final Office Action mailed Sep. 4, 2020”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,728, Final Office Action mailed Jan. 31, 2022”, 19 pages. [cited by applicant]
“U.S. Appl. No. 16/156,728, Non Final Office Action mailed Jul. 7, 2021”, 19 pages. [cited by applicant]
“U.S. Appl. No. 16/156,728, Non Final Office Action mailed Dec. 23, 2020”, 22 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,728, Response filed Mar. 18, 2021 to Non Final Office Action mailed Dec. 23, 2020”, 17 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,728, Response filed Oct. 6, 2021 to Non Final Office Action mailed Jul. 7, 2021”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,728, Response filed Oct. 12, 2020 to Restriction Requirement mailed Aug. 21, 2020”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,728, Restriction Requirement mailed Aug. 21, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,747, Corrected Notice of Allowability mailed May 18, 2021”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,747, Corrected Notice of Allowability mailed Sep. 15, 2021”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,747, Non Final Office Action mailed Oct. 21, 2020”, 9 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,747, Notice of Allowance mailed Apr. 26, 2021”, 5 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,747, Response filed Jan. 20, 2021 to Non Final Office Action mailed Oct. 21, 2020”, 13 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,747, Response filed Jul. 27, 2020 to Restriction Requirement mailed Jun. 5, 2020”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/156,747, Restriction Requirement mailed Jun. 5, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/652,896, Notice of Allowance mailed Jan. 28, 2022”, 7 pgs. [cited by applicant]
“U.S. Appl. No. 16/652,896, Preliminary Amendment Filed Apr. 1, 2020”, 8 pgs. [cited by applicant]
“U.S. Appl. No. 16/652,896, Supplemental Notice of Allowability mailed Feb. 9, 2022”, 2 pgs. [cited by applicant]
“U.S. Appl. No. 17/385,385, Preliminary Amendment filed Aug. 18, 2021”, 7 pgs. [cited by applicant]
“Australian Application Serial No. 2018347354, First Examination Report mailed Dec. 14, 2020”, 6 pgs. [cited by applicant]
“Australian Application Serial No. 2018347354, Response filed Jan. 29, 2021 to First Examination Report mailed Dec. 14, 2020”, 29 pgs. [cited by applicant]
“Australian Application Serial No. 2018347354, Response filed Apr. 16, 2021 to Subsequent Examiners Report mailed Feb. 11, 2021”, 18 pgs. [cited by applicant]
“Australian Application Serial No. 2018347354, Subsequent Examiners Report mailed Feb. 11, 2021”, 5 pgs. [cited by applicant]
“Australian Application Serial No. 2021209337, First Examination Report mailed Aug. 9, 2021”, 4 pgs. [cited by applicant]
“Australian Application Serial No. 2021209337, Response filed Oct. 12, 2021 to First Examination Report mailed Aug. 9, 2021”, 8 pgs. [cited by applicant]
“Australian Application Serial No. 2021209337, Response filed Oct. 15, 2021 to Subsequent Examiners Report mailed Oct. 14, 2021”, 6 pgs. [cited by applicant]
“Australian Application Serial No. 2021209337, Subsequent Examiners Report mailed Oct. 14, 2021”, 3 pgs. [cited by applicant]
“Canadian Application Serial No. 3,078,736, Office Action Mailed Feb. 1, 2022”, 5 pages. [cited by applicant]
“Canadian Application Serial No. 3,078,736, Office Action mailed Apr. 29, 2021”, 5 pages. [cited by applicant]
“Canadian Application Serial No. 3,078,736, Response filed Aug. 26, 2021 to Office Action mailed Apr. 29, 2021”, 18 pgs. [cited by applicant]
“Chinese Application Serial No. 201880066636.2, Office Action mailed May 31, 2021”, with English translation, 14 pages. [cited by applicant]
“Chinese Application Serial No. 201880066636.2, Response filed Sep. 13, 2021 to Office Action mailed May 31, 2021”, with English claims, 14 pages. [cited by applicant]
“European Application Serial No. 18796230.3, Communication Pursuant to Article 94(3) EPC mailed Apr. 22, 2021”, 4 pgs. [cited by applicant]
“European Application Serial No. 18796230.3, Response filed Nov. 2, 2021 to Communication Pursuant to Article 94(3) EPC mailed Apr. 22, 2021”, 20 pgs. [cited by applicant]
“European Application Serial No. 18796230.3, Response to Communication pursuant to Rules 161(1) and 162 EPC filed Nov. 30, 2020”, 22 pgs. [cited by applicant]
“European Application Serial No. 18797274.0, Response to Communication pursuant to Rules 161(1) and 162 EPC filed Dec. 9, 2020”, 18 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/055218, International Preliminary Report on Patentability mailed Apr. 23, 2020”, 7 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/055218, International Search Report mailed Jan. 30, 2019”, 5 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/055218, Written Opinion mailed Jan. 30, 2019”, 5 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/055232, International Preliminary Report on Patentability mailed Apr. 23, 2020”, 12 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/055232, International Search Report mailed Mar. 19, 2019”, 8 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/055232, Invitation to Pay Additional Fees and Partial Search Report mailed Jan. 24, 2019”, 14 pgs. [cited by applicant]
“International Application Serial No. PCT/US2018/055232, Written opinion mailed Mar. 19, 2019”, 12 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-520521, Final Notification of Reasons for Refusal mailed Feb. 22, 2022”, with English translation, 5 pages. [cited by applicant]
“Japanese Application Serial No. 2020-520521, Final Notification of Reasons for Refusal mailed Nov. 2, 2021”, with English translation, 4 pages. [cited by applicant]
“Japanese Application Serial No. 2020-520521, Notification of Reasons for Refusal mailed May 25, 2021”, with English translation, 9 pages. [cited by applicant]
“Japanese Application Serial No. 2020-520521, Response filed Jan. 13, 2022 to Final Notification of Reasons for Refusal mailed Nov. 2, 2021”, with English claims, 17 pages. [cited by applicant]
“Japanese Application Serial No. 2020-520521, Response filed Aug. 12, 2021 to Notification of Reasons for Refusal mailed May 25, 2021”, with English claims, 21 pages. [cited by applicant]
“Smith & Nephew”, Legion Cones Surgical Technique V1, (Jan. 2017), 36 pgs. [cited by applicant]
“U.S. Appl. No. 16/652,896, Supplemental Notice of Allowability mailed May 11, 2022”, 2 pgs. [cited by applicant]
“Japanese Application Serial No. 2020-520521, Response filed Apr. 27, 2022 to Final Notification of Reasons for Refusal mailed Feb. 22, 2022”, with English claims, 11 pages. [cited by applicant]
“Canadian Application Serial No. 3,078,736, Response filed Jun. 1, 2022 to Office Action Mailed Feb. 1, 2022”, 23 pgs. [cited by applicant]
“Australia Application Serial No. 2022200138, First Examination Report mailed Sep. 23, 2022”, 3 pgs. [cited by applicant]
U.S. Appl. No. 16/156,728, filed Oct. 10, 2018, Revision Knee Arthroplasty Methods and Instruments. [cited by applicant]
U.S. Appl. No. 16/156,747 now U.S. Pat. No. 11,141,290, filed Oct. 10, 2018, Revision Knee Arthroplasty Methods and Instruments. [cited by applicant]
U.S. Appl. No. 17/385,385, filed Jul. 26, 2021, Revision Knee Arthroplasty Methods and Instruments. [cited by applicant]
U.S. Appl. No. 16/047,463 now U.S. Pat. No. 10,987,225, filed Jul. 27, 2018, Systems and Methods for Attaching Sleeve or Cone in Prosthetic Implant Having a Stem. [cited by applicant]
U.S. Appl. No. 16/652,896, filed Apr. 1, 2020, Implantation Cradle. [cited by applicant]
“Chinese Application Serial No. 202210322683.7, Response Filed Jul. 1, 2025 to Office Action mailed Mar. 13, 2025”, W/ English Claims, 17 pgs. [cited by applicant]
“Australia Application Serial No. 2022200138, Response filed Nov. 15, 2022 First Examination Report mailed Sep. 23, 2022”, 10 pgs. [cited by applicant]
“Australia Application Serial No. 2022200138, Subsequent Examiners Report mailed Dec. 1, 2022”, 3 pgs. [cited by applicant]
“Australia Application Serial No. 2022200138, Response filed Jan. 31, 2023 to Subsequent Examiners Report mailed Dec. 1, 2022”, 9 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-125533, Notification of Reasons for Refusal mailed May 9, 2023”, w English Translation, 8 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-125533, Response filed Aug. 7, 2023 to Notification of Reasons for Refusal mailed May 9, 2023”, w English claims, 20 pgs. [cited by applicant]
“European Application Serial No. 22208169.7, Extended European Search Report mailed Oct. 4, 2023”, 7 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-125533, Final Notification of Reasons for Rejection mailed Sep. 26, 2023”, W English Translation, 6 pgs. [cited by applicant]
“Japanese Application Serial No. 2022-125533, Response Filed Dec. 13, 2023 to Final Notification of Reasons for Rejection mailed Sep. 26, 2023”, w English Claims, 11 pgs. [cited by applicant]
“European Application Serial No. 22208169.7, Response filed Apr. 29, 2024 to Extended European Search Report mailed Oct. 4, 2023”, 31 pgs. [cited by applicant]
“Australian Application Serial No. 2023202761, First Examination Report mailed May 31, 2024”, 4 pgs. [cited by applicant]
“Australian Application Serial No. 2023202761, Response filed Aug. 9, 2024 to First Examination Report mailed May 31, 2024”, 9 pgs. [cited by applicant]
“Australian Application Serial No. 2023202761, Subsequent Examination Report mailed Sep. 4, 2024”, 3 pgs. [cited by applicant]
“U.S. Appl. No. 17/385,385, Restriction Requirement mailed Oct. 9, 2024”, 6 pgs. [cited by applicant]
“Australian Application Serial No. 2023202761, Response filed Oct. 14, 2024 to Subsequent Examination Report mailed Sep. 4, 2024”, 12 pgs. [cited by applicant]
“U.S. Appl. No. 17/385,385, Response filed Dec. 5, 2024 to Restriction Requirement mailed Oct. 9, 2024”, 6 pgs. [cited by applicant]
“Canadian Application Serial No. 3,207,198, Examiners Rule 86(2) Requisition mailed Dec. 2, 2024”, 4 pgs. [cited by applicant]
“U.S. Appl. No. 17/385,385, Non Final Office Action mailed Feb. 12, 2025”, 20 pgs. [cited by applicant]
“Japanese Application Serial No. 2024-032855, Notification of Reasons for Rejection mailed Jan. 21, 2025”, W English Translation, 8 pgs. [cited by applicant]
“Canadian Application Serial No. 3,207,198, Response filed Mar. 4, 2025 to Examiners Rule 86(2) Requisition mailed Dec. 2, 2024”, 13 pgs. [cited by applicant]
“Japanese Application Serial No. 2024-032855, Response filed Apr. 10, 2025 to Notification of Reasons for Rejection mailed Jan. 21, 2025”, W English Claims, 12 pgs. [cited by applicant]
“Chinese Application Serial No. 202210322683.7, Office Action mailed Mar. 13, 2025”, W English Translation, 14 pgs. [cited by applicant]
“U.S. Appl. No. 17/385,385, Response filed May 12, 2025 to Non Final Office Action mailed Feb. 12, 2025”, 16 pgs. [cited by applicant]
“U.S. Appl. No. 17/385,385, Final Office Action mailed Aug. 19, 2025”, 19 pgs. [cited by applicant]
“U.S. Appl. No. 17/385,385, Examiner Interview Summary mailed Oct. 24, 2025”, 3 pgs. [cited by applicant]
“Australian Application Serial No. 2025200297, First Examination Report mailed Dec. 9, 2025”, 6 pgs. [cited by applicant]
“Chinese Application Serial No. 202210322683.7, Office Action mailed Oct. 20, 2025”, w/English translation, 9 pgs. [cited by applicant]
“Canadian Application Serial No. 3,207,198, Examiners Rule 86(2) Report mailed Feb. 6, 2026”, 4 pgs. [cited by applicant]
“Australian Application Serial No. 2025200297, Response filed Feb. 16, 2026 to First Examination Report mailed Dec. 9, 2025”, W English Claims, 19 pgs. [cited by applicant]
“Chinese Application Serial No. 202210322683.7, Response Filed Dec. 17, 2025 to Office Action mailed Oct. 20, 2025”, w/English Claims, 14 pgs. [cited by applicant]
“Chinese Application Serial No. 202210322683.7, Response to Examiner Telephone Interview Filed Mar. 16, 2026”, w/English Claims, 5 pgs. [cited by applicant]
“Australian Application Serial No. 2025200297, Subsequent Examination Report mailed Mar. 23, 2026”, 4 pgs. [cited by applicant]
“European Application Serial No. 26156130.2, Extended European Search Report mailed Apr. 9, 2026”, 8 pgs. [cited by applicant]